Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-06-18 EDT			5-day change	1st Jan Change
380.50 ^DKK	+0.90%		-21.59%	-46.82%

11:37am	Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	RE
06-13	Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	RE

Zealand Pharma A/S - Shareholder/Analyst Call

Published on 2022-03-30 at 10:30

Presentation Operator Message
Operator (Operator)

Good morning, everyone, and welcome to the Zealand Pharma's Corporate Update Conference Call. Today's call is being recorded. On the call this morning,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Zealand Pharma A/S

Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial	11:37am	RE
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	06-13	RE
Zealand Pharma A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 04:00 PM	06-11
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial	06-10	RE
Zealand Pharma A/S Submits Marketing Authorization Application to the European Medicines Agency for Glepaglutide in Short Bowel Syndrome	06-02	CI
Zealand Pharma Files EU Marketing Authorization Application for Short Bowel Syndrome Treatment	06-02	MT
Zealand Pharma Applies To EMA For Marketing Authorization For Glepaglutide In Short Bowel Syndrome	06-02	RE
European stocks recover after Trump delays EU tariffs in hopes of deal	05-26	RE
Danish Biotech Zealand Pharma Names Chief Development Officer	05-20	MT
Zealand Pharma A/S Appoints Steven Johnson as Chief Development Officer	05-19	CI
Deutsche Bank lowers its target price for Zealand Pharma to 485 Danish kroner (750), reiterates hold	05-19	FW
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
Denmark says Trump's drug pricing order is a step in the wrong direction	05-16	RE
Zealand Pharma A/S Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:00 AM	05-14
Zealand Pharma A/S Announces Closing of Collaboration and License Agreement with Roche	05-09	CI
DNB lowers target price for Zealand Pharma to DKK 950 (1,000), reiterates buy recommendation - BN	05-09	FW
Zealand Pharma-Roche Deal for Obesity Drug Candidate Takes Effect	05-09	MT
Goldman Sachs lowers target price for Zealand Pharma to DKK 806 (USD 873), reiterates buy rating - BN	05-09	FW
SEB lowers target price for Zealand Pharma to DKK 780 (850), reiterates buy recommendation - BN	05-09	FW
Zealand Pharma A/S, Q1 2025 Earnings Call, May 08, 2025	05-08
Zealand Pharma Keeps Guidance For 2025 Unchanged	05-08	RE
Zealand Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Kempen Lowers Zealand Pharma PT, Keeps at Buy	05-05	MT
Kempen lowers target price for Zealand Pharma to DKK 750 (900), reiterates buy recommendation - BN	05-05	FW
DNB lowers target price for Zealand Pharma to DKK 1,000 (1,150), reiterates buy recommendation - BN	04-30	FW